BURINEX INJECTION 0.5 MG/ML [SIN01421P]

Product Info

BURINEX INJECTION 0.5 MG/ML

[SIN01421P]

4.1 Therapeutic indications
Burinex® is indicated whenever diuretic therapy is required in the treatment of oedema e.g. associated with congestive heart failure, cirrhosis of the liver, renal diseases including the nephrotic syndrome. Acute pulmonary oedema, drug induced fluid retention, and drug poisoning that can be treated by forced diuresis. Hypertension.

4.2 Posology and method of administration
Usually 1–2 mg intravenously or intramuscularly.
Pulmonary oedema:
Initially 2 mg by intravenous injection.
This can be repeated, if necessary, after 20 minutes. In those conditions in which an infusion is appropriate, 2–5 mg may be given in 500 ml infusion fluid over 30–60 minutes.

Renal failure:
2–10 mg in 500 ml infusion fluid given over a period of 30–60 minutes. Repeated, if required, at intervals of 6–8 hours.

Drug poisoning with salicylates or barbiturates:
Initially, 2 mg intravenously, followed by 1 mg every 4 hours. Totally, 7 mg in the course of 24 hours. The usual procedure for forced alkaline diuresis should be followed. Burinex® injection may be added to the commonly used infusion fluids based on glucose, sodium chloride, sodium bicarbonate, or potassium chloride.

4.3 Contraindications

• Hypersensitivity to formaldehyde (see Section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

• Hypersensitivity to active substance or to any of the excipients

• Severe electrolyte depletion

• Persisting anuria

• Hepatic encephalopathy including coma